Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 7, 2006; 12(21): 3386-3392
Published online Jun 7, 2006. doi: 10.3748/wjg.v12.i21.3386
Published online Jun 7, 2006. doi: 10.3748/wjg.v12.i21.3386
Table 3 Harvey-Bradshaw index, CD patients
| t/d | All | Responder | Non-responder | Operated |
| (n = 24) | (n = 8) | (n = 16) | (n = 7) | |
| 1 | 14.9 (4 - 29) | 12.8 (4 - 26) | 15.9 (9 - 29) | 16.9 (11 - 29) |
| 3 | 11.2 (2 - 22) | 7.9 (2 - 13) | 12.9 (2 - 22) | 16.2 (11 - 22) |
| 7 | 7.7 (1 - 19) | 5.8 (1 - 19) | 9.6 (2 - 13) | 11.5 (10 - 13) |
| 28 | 4.2 (1 - 9) | 1.9 (1 - 3) | 6.9 (4 - 9) | NA |
-
Citation: Ljung T, Lundberg S, Varsanyi M, Johansson C, Schmidt PT, Herulf M, Lundberg JO, Hellström PM. Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: Responders
versus nonresponders. World J Gastroenterol 2006; 12(21): 3386-3392 - URL: https://www.wjgnet.com/1007-9327/full/v12/i21/3386.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i21.3386